Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review.

TitreOncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review.
Publication TypeJournal Article
Year of Publication2022
AuthorsAndré L, Antherieu G, Boinet A, Bret J, Gilbert T, Boulahssass R, Falandry C
JournalCancers (Basel)
Date Published2022 May 17

Fatigue is a highly prevalent symptom in both cancer patients and the older population, and it contributes to quality-of-life impairment. Cancer treatment-related fatigue should thus be included in the risk/benefit assessment when introducing any treatment, but tools are lacking to a priori estimate such risk. This scoping review was designed to report the current evidence regarding the frequency of fatigue for the different treatment regimens proposed for the main cancer indications, with a specific focus on age-specific data, for the following tumors: breast, ovary, prostate, urothelium, colon, lung and lymphoma. Fatigue was most frequently reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) versions 3 to 5. A total of 324 regimens were analyzed; data on fatigue were available for 217 (67%) of them, and data specific to older patients were available for 35 (11%) of them; recent pivotal trials have generally reported more fatigue grades than older studies, illustrating increasing concern over time. This scoping review presents an easy-to-understand summary that is expected to provide helpful information for shared decisions with patients regarding the anticipation and prevention of fatigue during each cancer treatment.

Alternate JournalCancers (Basel)
PubMed ID35626074
PubMed Central IDPMC9139887
Grant ListBoard 2016 / / Teva Pharmaceuticals (France) /